• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管内皮生长因子及其可溶性受体-1和-2在虹膜新生血管形成及新生血管性青光眼中的作用

Vascular endothelial growth factor and its soluble receptors-1 and -2 in iris neovascularization and neovascular glaucoma.

作者信息

Noma Hidetaka, Mimura Tatsuya, Yasuda Kanako, Shimura Masahiko

机构信息

Department of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, Tokyo, Japan.

出版信息

Ophthalmologica. 2014;232(2):102-9. doi: 10.1159/000360303. Epub 2014 Jun 18.

DOI:10.1159/000360303
PMID:24942011
Abstract

Concentrations of vascular endothelial growth factor (VEGF), soluble VEGF receptor-1 (sVEGFR-1) and soluble VEGF receptor-2 (sVEGFR-2) were measured by enzyme-linked immunosorbent assay in 27 proliferative diabetic retinopathy patients who had iris neovascularization (INV) with or without neovascular glaucoma (NVG). The 27 eyes were divided into two groups, consisting of INV without elevation of the intraocular pressure (IOP; INV group) and INV with elevated IOP (NVG group). Ten patients with an idiopathic macular hole were used as the controls. The vitreous levels of VEGF, sVEGFR-1 and sVEGFR-2 showed a significant increase across the three groups. In the INV and NVG groups, the vitreous level of VEGF showed a significant correlation with the levels of sVEGFR-1 and sVEGFR-2. There was also a significant correlation between the vitreous levels of sVEGFR-1 and sVEGFR-2. These results suggest that the vitreous levels of sVEGFR-1 and sVEGFR-2 are dependent on VEGF in patients who have INV with or without NVG.

摘要

采用酶联免疫吸附测定法,对27例患有虹膜新生血管(INV)伴或不伴新生血管性青光眼(NVG)的增殖性糖尿病视网膜病变患者,检测其血管内皮生长因子(VEGF)、可溶性VEGF受体-1(sVEGFR-1)和可溶性VEGF受体-2(sVEGFR-2)的浓度。这27只眼被分为两组,即眼压未升高的INV组(INV组)和眼压升高的INV组(NVG组)。选取10例特发性黄斑裂孔患者作为对照。三组患者玻璃体中VEGF、sVEGFR-1和sVEGFR-2水平均显著升高。在INV组和NVG组中,玻璃体VEGF水平与sVEGFR-1和sVEGFR-2水平显著相关。sVEGFR-1和sVEGFR-2的玻璃体水平之间也存在显著相关性。这些结果表明,在患有或未患有NVG的INV患者中,玻璃体中sVEGFR-1和sVEGFR-2水平依赖于VEGF。

相似文献

1
Vascular endothelial growth factor and its soluble receptors-1 and -2 in iris neovascularization and neovascular glaucoma.血管内皮生长因子及其可溶性受体-1和-2在虹膜新生血管形成及新生血管性青光眼中的作用
Ophthalmologica. 2014;232(2):102-9. doi: 10.1159/000360303. Epub 2014 Jun 18.
2
Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy.可溶性血管内皮生长因子受体-1在增生性糖尿病视网膜病变玻璃体中的作用。
Ophthalmology. 2008 Nov;115(11):1916-22. doi: 10.1016/j.ophtha.2008.06.025. Epub 2008 Aug 21.
3
Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.玻璃体内注射贝伐单抗治疗41例连续性缺血性视网膜疾病继发的虹膜新生血管和新生血管性青光眼。
Ophthalmology. 2008 Sep;115(9):1571-80, 1580.e1-3. doi: 10.1016/j.ophtha.2008.02.026. Epub 2008 Apr 28.
4
Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy.玻璃体切除术后增殖性糖尿病视网膜病变患者玻璃体腔内血管内皮生长因子持续分泌
Ophthalmology. 2004 Oct;111(10):1880-4. doi: 10.1016/j.ophtha.2004.03.035.
5
Aqueous Inflammation and Ischemia-Related Biomarkers in Neovascular Glaucoma with Stable Iris Neovascularization.稳定虹膜新生血管的新生血管性青光眼的水样炎症和与缺血相关的生物标志物。
Curr Eye Res. 2020 Dec;45(12):1504-1513. doi: 10.1080/02713683.2020.1762226. Epub 2020 May 18.
6
Angiogenic and inflammatory biomarker levels in aqueous humor and vitreous of neovascular glaucoma and proliferative diabetic retinopathy.新生血管性青光眼和增殖性糖尿病视网膜病变眼内液和玻璃体内血管生成和炎症生物标志物水平。
Int Ophthalmol. 2020 Feb;40(2):467-475. doi: 10.1007/s10792-019-01207-4. Epub 2019 Dec 4.
7
Soluble vascular endothelial growth factor receptor-2 and inflammatory factors in macular edema with branch retinal vein occlusion.视网膜分支静脉阻塞伴黄斑水肿患者的可溶性血管内皮生长因子受体-2 和炎症因子。
Am J Ophthalmol. 2011 Oct;152(4):669-677.e1. doi: 10.1016/j.ajo.2011.04.006. Epub 2011 Jul 2.
8
Short Communication: Increase of Sialylated N-Glycansin Eyes with Neovascular Glaucoma Secondary to Proliferative Diabetic Retinopathy.简短通讯:增殖性糖尿病视网膜病变继发新生血管性青光眼患者眼部唾液酸化N-聚糖增加
Curr Eye Res. 2016 May;41(5):721-4. doi: 10.3109/02713683.2015.1068816. Epub 2015 Jul 15.
9
Angiogenesis regulatory factors in the vitreous from patients with proliferative diabetic retinopathy.增生型糖尿病视网膜病变患者玻璃体内的血管生成调控因子。
Acta Diabetol. 2013 Aug;50(4):545-51. doi: 10.1007/s00592-011-0330-9. Epub 2011 Sep 25.
10
Vitreous levels of soluble vascular endothelial growth factor receptor (VEGFR)-1 in eyes with vitreoretinal diseases.眼内疾病患者玻璃体中可溶性血管内皮生长因子受体 (VEGFR)-1 的水平。
Br J Ophthalmol. 2011 Dec;95(12):1745-8. doi: 10.1136/bjophthalmol-2011-300139. Epub 2011 Jun 30.

引用本文的文献

1
What is the impact of intravitreal injection of conbercept on neovascular glaucoma patients: a prospective, interventional case series study.玻璃体内注射康柏西普对新生血管性青光眼患者的影响:一项前瞻性、干预性病例系列研究。
BMC Ophthalmol. 2019 Jun 11;19(1):128. doi: 10.1186/s12886-019-1138-6.
2
Review of Biomarkers in Ocular Matrices: Challenges and Opportunities.眼基质生物标志物的研究:挑战与机遇
Pharm Res. 2019 Jan 23;36(3):40. doi: 10.1007/s11095-019-2569-8.
3
The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy.
眼科抗血管内皮生长因子(VEGF)药物时代、VEGF与抗VEGF治疗
Cent Eur J Immunol. 2016;41(3):311-316. doi: 10.5114/ceji.2016.63132. Epub 2016 Oct 25.
4
Ranibizumab Plus Combined Surgery for Treatment of Neovascular Glaucoma with Vitreous Hemorrhage.雷珠单抗联合手术治疗伴有玻璃体积血的新生血管性青光眼
Chin Med J (Engl). 2015 Aug 5;128(15):2078-83. doi: 10.4103/0366-6999.161371.
5
Analysis of the influence of type of diabetes mellitus on the development and type of glaucoma.糖尿病类型对青光眼发生发展及类型的影响分析
Med Arch. 2015 Feb;69(1):34-7. doi: 10.5455/medarh.2015.69.34-37. Epub 2015 Feb 21.